Navigation Links
Children taking steroids for asthma are slightly shorter than peers
Date:9/3/2012

AUDIO: Children who use inhaled steroid drugs for asthma end up slightly shorter at their full adult height than children who dont use the drugs, new results from a comprehensive asthma...

Click here for more information.

Children who use inhaled steroid drugs for asthma end up slightly shorter at their full adult height than children who don't use the drugs, new results from a comprehensive asthma study show.

The findings will be presented Sept. 3 at the European Respiratory Society meeting in Vienna, Austria, and published online the same day in the New England Journal of Medicine. The study's senior author is Robert C. Strunk, MD, the Donald Strominger Professor of Pediatrics at Washington University School of Medicine in St. Louis.

The study involved more than 1,000 children ages 5-12 who were treated for mild to moderate asthma as part of the Childhood Asthma Management Program (CAMP) clinical trial. The children received treatment for more than four years at eight centers, including Washington University School of Medicine. They were divided into three groups: one received twice-daily budesonide, an inhaled corticosteroid medication; a second group received nedocromil, an inhaled non-steroid medication; and a third group received a placebo. All children received albuterol, a fast-acting drug for relief of acute asthma symptoms, and oral corticosteroids as needed for asthma symptoms.

The researchers followed 943 participants in the trial at regular intervals until they reached adult height. Females were considered to be at adult height at age 18 or older and males at age 20 or older, Strunk says. In the first 4 1/2 years after the end of the trial, researchers took patients' height and weight every six months. Over the next eight years, height and weight were measured once or twice a year.

The mean adult height was about one-half inch, or 1.2 centimeters, shorter in the group that received budesonide than in the patients who received nedocromil or placebo. The patients who experienced the slower growth were primarily between 5-11 years old when they began using budesonide.

The slower growth took place only in the first two years of the four-year study. As the study progressed, the children who took the budesonide remained one-half inch shorter through adulthood than the children who did not use the drug, says Strunk, who treats children with asthma at St. Louis Children's Hospital.

"This was surprising because in previous studies, we found that the slower growth would be temporary, not affecting adult height," Strunk says. "But none of those studies followed patients from the time they entered the study until they had reached adult height."

Strunk, CAMP study chair, says researchers considered various factors that also might have contributed to the slower growth rate, including gender, age at the time the child entered the trial, how long the child had had asthma, as well as ethnicity, severity of asthma and reactivity to a skin test for allergies.

"We found it made no difference if they were boys or girls or how long they had had asthma, or any other of these factors," Strunk says. "We also looked at the height of the parents, and that didn't have any impact, either."

Pediatric asthma specialists at St. Louis Children's Hospital keep a close watch on the growth of their patients who use inhaled steroids, Strunk says. They are measured at every visit, and physicians keep a growth curve.

"If a child is not growing as they should, we may reduce their steroid dose," he says. "But we think that the half-inch of lowered adult height must be balanced against the well-established benefit of inhaled corticosteroids in controlling persistent asthma. We will use the lowest effective dose to control symptoms to minimize concerns about effects on adult height."

Inhaled corticosteroids such as budesonide are the most effective form of anti-inflammatory treatment for asthma, which affects 9.4 percent of U.S. children. The drugs control symptoms and improve pulmonary function. Results from the original CAMP trial, begun in the mid-1990s, showed that using budesonide twice daily led to fewer hospitalizations and urgent care visits, fewer days in which additional asthma medications were needed and a reduced need for albuterol. Using nedocromil twice daily reduced urgent care visits and courses of oral steroids for severe symptoms but did not affect the number of hospitalizations, symptoms or airway responsiveness.


'/>"/>
Contact: Judy Martin Finch
martinju@wustl.edu
314-286-0105
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. In children born with severe heart defect, surgical management has little effect on neuro outcomes
3. Children Born to Obese Moms May Face Higher Autism Risk: Study
4. Supporting LGB children may influence their long-term health, BU study finds
5. Out-of-hand tree nut consumption associated with better diet quality in children and adults
6. BASPCAN - UK-wide increase in number of children
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. U.S. Children Exposed to Hours of Background TV Daily
9. Leaders in childrens health to gather in Boston
10. Dietary changes help some children with ADHD
11. Bullied Children at Greater Risk for Self-Harm, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 23, 2017 , ... Somnoware, a leading provider of digital ... to automatically connect and initialize all their devices with one click. This new ... installed on first use and then monitors device changes automatically. With this new ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s ... accountant at the Firm, will participate in the 40th Annual "Empire State Building Run ... race up 1,576 steps, a vertical distance equal to about a fifth of a ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... taught by healthcare management and evaluation leaders with decades of experience who remain ... in the United States healthcare system, there is a renewed demand for versatile, ...
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary ... will serve as a healthcare industry expert at the 2017 Sector Summit hosted ... by Inside Indiana Business host Gerry Dick, will feature an employer and an ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 Endo International ... Trade Commission (FTC) today filed a joint motion in ... California seeking the entry of ... Order resolves all disputes between the FTC and Endo ... in connection with its Opana® ER and Lidoderm® products.  ...
(Date:1/23/2017)... YORK , Jan. 23, 2017 MouthWatch LLC ... Camera was ranked as the best intraoral camera on ... taking the #2 spot overall. The #1 product was the ... said the MouthWatch intraoral camera was "…incredibly popular because it ... the camera has a small sticker price, it doesn,t sacrifice ...
(Date:1/23/2017)... , Jan. 23, 2017  Allergan plc, (NYSE: ... continued support of the International Headache Academy (IHA). Designed to ... and research scientists, IHA offers a three-day, intensive overview on ... Allergan has been the sole sponsor since the inception of ... and iHEAD in Europe in 2014. ...
Breaking Medicine Technology: